EpiAxis heads to the J.P Morgan 40th Annual Healthcare Conference

Following a successful presentation at the Australia-Taiwan Biotech Investment & Partnership Forum earlier this month, EpiAxis Therapeutics will be taking its new corporate presentation to the J.P. Morgan 40th Annual Healthcare Conference.

The conference will be held in San Francisco from January 10-13, 2022.

“The J.P. Morgan 40th Annual Healthcare Conference is the largest and most informative health care investment symposium in the industry,” said EpiAxis CEO Dr Jeremy Chrisp. “It connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.”

Register Interest

In 2021, public and private companies delivered presentations to more than 8000 conference participants.

For 2022, AusBiotech is hosting a virtual Australian Showcase during the conference, highlighting companies at the forefront of medical innovation. EpiAxis will share its new corporate presentation to global investors and potential partners at this conference.

In partnership with AusBiotech, EpiAxis took part in the Australia-Taiwan Biotech Investment & Partnership Forum in early November. Organised by the Australian Office Taipei and the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), the forum aimed to connect the biotech and pharma industries in the two nations.

More than 60 guests joined the forum, which was held during the BioTaiwan Exhibition, including several major biotech companies, venture capitalists, BIO industry members, event partners and journalists from bio magazines.

“It was exciting to share the latest updates from EpiAxis with industry and investors in Taiwan,” said Dr Chrisp. “There is great potential for our epigenetics pipeline in the Asian market and we look forward to following up on the valuable connections that were made during the forum.”

About The Company

EpiAxis Therapeutics Pty Ltd (“EpiAxis”) is a privately funded, translational drug development company developing novel epigenetic cancer therapeutics. The Company, which was established in 2015, was based on the pioneering work of Professor Sudha Rao regarding the role of lysine-specific demethylase 1 (“LSD1”) in cancer progression and metastasis. EpiAxis’ key point of differentiation is the way that their LSD1 inhibitors target dormant cancer cells and epigenetically re-programming them back to a normal cell phenotype, thereby decreasing their resistance to therapies, whilst reinvigorating the immune system.

Register Interest